X
API Suppliers
US DMFs Filed
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
Other Suppliers
USA (Orange Book)
Europe
Canada
Australia
South Africa
Uploaded Dossiers
0
U.S. Medicaid
Annual Reports
https://www.prnewswire.com/news-releases/ideaya-biosciences-announces-proffered-paper-oral-presentation-at-esmo-2023-for-phase-2-clinical-data-update-for-darovasertib-and-crizotinib-combination-in-metastatic-uveal-melanoma-301958315.html
https://www.prnewswire.com/news-releases/ideaya-biosciences-announces-phase-2-expansion-of-darovasertib-and-crizotinib-combination-in-gnaq11-metastatic-cutaneous-melanoma-301956860.html
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=217581
https://media.ideayabio.com/2023-05-16-IDEAYA-Expands-Clinical-Trial-Collaboration-and-Supply-Agreements-with-Pfizer-to-Support-Registrational-Trial-Evaluating-Darovasertib-and-Crizotinib-Combination-in-First-Line-Metastatic-Uveal-Melanoma
https://www.biopharmadive.com/news/pharma-drug-price-increases-january-new-year/639564/
https://www.prnewswire.com/news-releases/ideaya-biosciences-receives-fast-track-designation-for-darovasertib-combination-therapy-with-crizotinib-for-the-treatment-of-metastatic-uveal-melanoma-301692961.html
https://endpts.com/pfizer-launches-rebate-program-for-rare-disease-patients-who-have-to-stop-taking-panzyga/
https://www.fiercepharma.com/pharma/pfizers-xalkori-scores-fda-nod-another-rare-alk-positive-disorder
https://pharmaphorum.com/news/fda-clears-xalkori-for-inflammatory-myofibroblastic-tumours/
https://www.prnewswire.com/news-releases/ideaya-and-pfizer-expand-clinical-trial-collaboration-and-supply-agreements-for-evaluation-of-darovasertib-and-crizotinib-combination-in-metastatic-uveal-melanoma-and-additional-cmet-driven-tumors-301501338.html
https://www.fiercepharma.com/marketing/takeda-value-based-drug-pricing-lung-cancer-alunbrig-pfizer-xalkori-discount-rebate
https://www.prnewswire.com/news-releases/ideaya-announces-dose-expansion-in-phase-12-study-of-darovasertib-and-crizotinib-combination-based-on-early-clinical-efficacy-in-first-combination-cohort-301287055.html
https://endpts.com/pfizers-xalkori-follow-up-which-smoked-the-older-drug-in-1st-line-patients-scores-double-win-at-the-fda/
https://www.europeanpharmaceuticalreview.com/news/140117/fda-approves-crizotinib-for-children-with-certain-anaplastic-large-cell-lymphomas/
https://www.businesswire.com/news/home/20210114006005/en/Pfizer%E2%80%99s-XALKORI%C2%AE-crizotinib-Approved-by-FDA-for-ALK-positive-Anaplastic-Large-Cell-Lymphoma-in-Children-and-Young-Adults
https://www.businesswire.com/news/home/20210114006005/en/Pfizer%E2%80%99s-XALKORI%C2%AE-crizotinib-Approved-by-FDA-for-ALK-positive-Anaplastic-Large-Cell-Lymphoma-in-Children-and-Young-Adults
https://ir.ideayabio.com/2021-01-05-IDEAYA-Biosciences-Doses-First-Patient-in-a-Phase-1-Combination-Study-of-IDE196-and-Crizotinib-a-cMET-Inhibitor
http://www.pmlive.com/pharma_news/fda_sets_january_decision_date_for_xalkori_in_alk-positive_lymphoma_1351463
https://www.prnewswire.com/news-releases/ideaya-and-pfizer-expand-clinical-trial-collaboration-and-supply-agreement-to-evaluate-clinical-combination-of-ide196-and-crizotinib-in-solid-tumors-harboring-gnaq-or-gna11-mutations-301137168.html
https://www.biospace.com/article/releases/fda-accepts-supplemental-new-drug-application-for-pfizer-s-xalkori-crizotinib-for-the-treatment-of-pediatric-alk-positive-anaplastic-large-cell-lymphoma-/
https://www.fiercepharma.com/pharma/esmo-pfizer-s-lorbrena-blows-xalkori-out-water-bid-for-front-line-alk-positive-lung-cancer
https://www.esmo.org/meetings/esmo-virtual-congress-2020/daily-reporter/daily-reporter-news/crown-trial-supports-lorlatinib-as-a-future-first-line-standard-treatment-in-alk-positive-non-small-cell-lung-cancer
https://www.fiercepharma.com/pharma/pfizer-s-lorbrena-makes-play-for-earlier-lung-cancer-use-xalkori-topping-data
https://www.fiercepharma.com/pharma/embargoed-til-weds-5-pm-asco-roche-s-alecensa-stays-top-xalkori-long-term-survival-showing
http://www.pharmatimes.com/news/nice_final_guidance_backs_pfizers_lorviqua_1340196
https://www.businesswire.com/news/home/20200224005128/en/Takeda-Announces-U.S.-FDA-Grants-Priority-Review/?feedref=JjAwJuNHiystnCoBq_hl-WBlLQO14j4QZPTyX5CYOnwC4VjN53jumZRlnzhBoBxGrCOi9QzgjCezTS3Nw_X6kJUrpSBm-Hav1w-UkdSlG3ltkRSnqzf6ourQGu_UA28CzZCGORvG0LE20YOvo49uqw==
https://www.fiercepharma.com/marketing/takeda-eyes-alunbrig-earlier-lung-cancer-use-as-2-year-data-trounce-pfizer-s-xalkori
https://endpts.com/merck-kgaa-touts-fda-breakthrough-status-blockbuster-potential-in-bid-to-investors/
http://www.pharmatimes.com/news/pairing_targeted_drugs_could_overcome_breast,_lung_cancer_treatment_resistance_1294450
https://endpts.com/roche-fields-first-approval-for-rozlytrek-in-the-run-up-to-a-showdown-with-eli-lilly-pfizer/
https://www.fiercepharma.com/pharma/pfizer-never-say-never-m-a-buys-oncology-innovator-array-for-11-4b
https://endpts.com/asco19-met-inhibitors-from-incyte-novartis-and-germanys-merck-face-off-for-rare-subset-of-nsclc-patients/
https://www.fiercebiotech.com/biotech/asco-death-turning-point-nsclc-trial-overshadows-82-orr
http://www.pharmafile.com/news/521969/pfizer-scores-conditional-european-approval-alk-positive-lung-cancer-lorviqua
https://www.statnews.com/2019/01/07/fda-plans-to-create-a-new-office-to-leverage-cutting-edge-science/
https://endpts.com/pfizer-racks-up-its-third-cancer-drug-ok-in-2-months-but-is-it-enough-to-replace-regular-price-hikes/
https://www.businesswire.com/news/home/20181019005217/en/Takeda-Present-Results-Phase-3-ALTA-1L-Trial
https://www.genomeweb.com/molecular-diagnostics/amoydx-lung-cancer-cdx-approved-south-korea#.W8VOAmgzbDd
https://www.fiercepharma.com/pharma-asia/big-pharma-s-cancer-drugs-take-50-plus-discount-for-china-s-insurance-scheme
http://www.pharmatimes.com/news/preliminary_nice_no_for_takedas_alunbrig_1254340
https://www.fiercepharma.com/marketing/takeda-alk-drug-alunbrig-trounces-pfizer-s-xalkori-bid-for-earlier-use
https://www.fiercepharma.com/pharma-asia/take-note-i-o-players-bristol-myers-to-sell-opdivo-china-at-half-its-u-s-price-report
https://www.biocentury.com/bc-extra/politics-policy/2018-08-17/china-unveils-cancer-drugs-medical-insurance-access-negotiation
https://www.reuters.com/article/us-roche-china/roches-alecensa-latest-beneficiary-of-faster-china-drug-approvals-idUSKCN1L50CJ?feedType=RSS&feedName=healthNews
Market Place
Share 
